

Nursing Now

CHALLENGE

a programme of The Burdett Trust for Nursing

Nursing Now Challenge Global Solutions Initiative



Supporting the creation of nurse
& midwife-led solutions to global
health challenges

The challenge

Design an innovative, nurse/ midwife-led AMR project to be implemented in your workplace or community.


Purpose

To elevate the voices and perspectives of nurses and midwives and provide them with the opportunity to collaborate and develop solutions to the challenges they face today.

Collaborating organisation

We are delighted to collaborate with the **AMR Futures Lab** at **Edinburgh Futures Institute** to bring Nursing Now Challenge members this new NNCGSI.

The EFI is a new interdisciplinary learning, research, and innovation center at the [University of Edinburgh](#). It is a hub for data-driven innovation and collaboration, with a focus on addressing complex global challenges across areas like creative industries, public services, and financial services. EFI is focused on tackling today's increasingly complex issues by bringing people and disciplines together to spark the unexpected and make better futures possible. The AMR Futures Lab is an emerging initiative that will turn evidence into adoption by harnessing transdisciplinary approaches to tackling AMR.



The AMR Futures Lab team



Professor Till Bachmann,

Chair of Molecular Diagnostics & Infection at the University of Edinburgh,
AMR Strategy Lead for Edinburgh Infectious Diseases,
Chair of the Edinburgh AMR Forum, & Founder of the AMR Futures Lab

He is an expert in point of care detection of infectious diseases and antimicrobial resistance, conducting research at the interface of biomarkers and rapid diagnostics. Till is an experienced network coordinator and strong proponent of transdisciplinary approaches to tackling antimicrobial resistance in a One Health and Global Health context including as coordinator of the UK-India DOSA projects (Diagnostics for One Health and User Driven Solutions for AMR), the JPIAMR Networks AMR Dx Global, AMR-Rapid Diagnostic Tests, Co-Director of the University of Edinburgh's Fleming Fund Fellowships Host Institution programme for Kenya, Uganda, Malawi and Zambia and as Task Lead in the IMI VALUE-Dx and partner in the JPIAMR network B2B2B AMRDx. Till has wide experience in a range of industrial and institutional advisory roles worldwide including as Chair of the Scientific Advisory Board of JPIAMR, panel member of the Longitude Prize on Antibiotics, Chair of the Programme Committee for the Pipeline Monday for ESCMID Global, and member of the One Health Self Steering Committee for Una Europa. Till works closely with international bodies to promote the development and uptake of AMR diagnostics including as Diagnostics Advisor for the Global AMR R&D Hub, founding member of the BEAM Alliance Diagnostics Taskforce, and as the co-Chair of the expert group for the WHO Landscape analysis of commercially available and pipeline IVD for fungal priority pathogens 2025 and the Landscape of Diagnostics for Bacterial Priority Pathogens.




Dr Maneesh Paul,

Lead Co-inventor & Programme Director of Enmetazobactam, a trained
Clinical Microbiologist, & Antimicrobial Stewardship Champion

Maneesh Paul is the co-inventor and Programme Lead of the first invented-in-India anti-infective molecule Enmetazobactam at Orchid Pharma, Chennai (India) that has been approved by the US FDA, and UK-MHRA, European Medicines Agency, and Indian CDSCO for marketing authorization in 2024. He is a clinical microbiologist who pursued basic and applied research discovering novel anti-infectives and characterizing several microbial genes and proteins. He has translated scientific accomplishments and leadership through patents and publications.

As a postdoctoral fellow, he trained in infectious diseases, specifically in molecular mechanisms of the pathogenesis of neonatal microbial meningitis at Johns Hopkins School of Medicine, USA, as well as the role of *A. actinomycetemcomitans* in the pathogenesis of atherosclerosis at Umeå University, Sweden. He was the ORISE Fellow at the Center for Biologics Evaluation and Research (CBER), USFDA researching on reverse vaccinology of *N. meningitidis*, and as an industrial fellow in the anti-infectives new drug discovery program at Dr Reddy's Laboratories, India.



Maneesh, in addition to leading the Enmetazobactam programme, also led the anti-infectives discovery research group, in India, co-inventing several pre-clinical candidates in anti-bacterial and anti-fungal space. He led post-graduate evidence-based medical research at St. Martha's Hospital, India, and advises several pharma and medical device companies. He led trans-disciplinary research at Acharya Institutes, Bengaluru, enabling it to become a research-based academic and research excellence campus.

In 2022 Maneesh founded Microvioma, India, a research-based organisation founded on verified science to participate in addressing the challenge of AMR & WHO's One Health mission by providing microbiology-based solutions & Stewardship initiatives.


Maneesh is an AMR stewardship champion through AMRACE (AMR Action Collaborative Engagement). He served as a member of the AMR Committee of the Infectious Diseases Society of America (USA) for three years and is a member of its research committee. He conferred the qualification as FIDSA (Fellow of IDSA) in 2024. Maneesh received his Master's degree in medical microbiology from Kasturba Medical College-MAHE and obtained a PhD from Gulbarga University, supported by Jean-Claire Lee of Harvard Medical School, Boston USA.



Denise Barrault,
Programme Manager, University of Edinburgh

Previously, Denise carried out the Operations and Financial management of the University of Edinburgh Fleming Fund Fellowships, a complex Antimicrobial Resistance (AMR) research and training project spanning 4 African Low- or Middle-Income Countries.

Previously, Den was Director of Novel Biology and Technology Partnerships at Exscientia, leading activities to establish new collaborations to drive innovation. Den also worked on establishing and managing large scale academic life science and medical research projects on the Scottish and European levels. In 2010 she joined SULSA (Scottish Universities Life Sciences Alliance) to co-ordinate life science strategy between Scotland's leading Universities. As Executive Director, where she established new research collaborations, she was a key member of the team that set up large public-private partnerships such as the European Lead Factory and the National Phenotypic Screening Centre. In 2015, Den was appointed as NPSC's Executive Director, where she was instrumental in the set-up of the Phenomics Discovery Initiative (PDi), a 4-year drug discovery collaboration between Janssen and the Universities of Dundee, Oxford and Edinburgh. PDi crowdsourced novel cellular phenotypes globally from academia and translated them into models that could be screened at scale, to industry standards, against pharma chemical libraries. Den has been involved in raising over €300m for public-private research partnerships in the life sciences.



GUIDELINES

How to get started

You are encouraged to participate in a launch webinar which will take place on **19th November at 2 pm (GMT)**.

During this webinar, you will receive detailed information about the theme of this challenge and the context within which it is set, guidance on developing your ideas, and key dates. You will also receive information about the prize for this NNCGSI.

To take part in this NNCGSI, you are required to prepare a short concept note which provides key information about you and your ideas.


Your concept note should be no more than **1,000 words** and it should be submitted by **30th January 2026** to challenge@nursingnow.global

What to include in your concept note?

- Name, job title and employer name
- Location
- Contact details including your email address

Context

- Describe the issues related to antimicrobial resistance in your country or region.
- Discuss the impact of antimicrobial resistance on your nursing/ midwifery practice.
- Outline the ways in which your experience could be used as a catalyst for change.




Your solution

- Describe your solution and how it will improve the situation in your workplace/ community.
- Explain how your experience has helped you to develop this idea.

Please ensure that you answer the following questions in your concept note...

- How will you address the challenges that you have identified?
- How will your solution improve outcomes and benefit patients and/or the target community?
- What makes your solution innovative? Include details of any digital platforms to be used
- Who is needed in order to bring this to life including financial considerations?
- Have you already identified and engaged with stakeholders to discuss your ideas?
- How would you spread the word and encourage wider uptake of this approach?
- Does your solution support the leadership development of early-career nurses and/ or midwives? If yes, please explain how.
- How would you evaluate the impact and success of your solution?



Conclusion

- Tell us about you and what motivated you to take part in this NNCGSI.
- Explain how participating in this initiative is supporting your career development and how you will use the contacts made and knowledge gained.

Selection process

- All submissions will be reviewed and five finalists will be selected to take part in an online interview
- Following this interview, three finalists will be selected as the winners of this NNCGSI
- Winners will receive mentoring from expert researchers in the field of AMR, providing invaluable guidance and support to develop their projects.

We encourage you to join our Facebook group, where you will find resources to support you in developing your ideas.

If you have any questions, please do not hesitate to contact challenge@nursingnow.global

**GOOD
luck!**